Lung cancer in 2013: state of the art therapy for metastatic disease

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

Volumn , Issue , 2013, Pages 339-346

  Shepherd, Frances A ^a   Bunn, Paul A ^a   Paz Ares, Luis ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; DOCETAXEL; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; PROTEIN TYROSINE KINASE; TAXOID;

ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; HUMAN; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; PEMETREXED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 84978054957     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.1200/EdBook_AM.2013.33.339     Document Type: Review

References (0)